| Jun 21 |
Sector Update: Health Care Stocks Gain in Late Afternoon
|
| Jun 21 |
Sarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't Last
|
| Jun 21 |
Top Stock Movers Now: FactSet, Sarepta Therapeutics, Spirit AeroSystems, and More
|
| Jun 21 |
US indexes open mixed, pharmaceutical stocks climb: Morning Brief
|
| Jun 21 |
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
|
| Jun 21 |
Stocks to Watch Friday: Nvidia, Micron, Sarepta, CarMax
|
| Jun 21 |
Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says
|
| Jun 21 |
Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment
|
| Jun 21 |
Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.
|
| Jun 21 |
Sarepta surges on expanded approval of muscular dystrophy drug
|
